Tobacco smoking is the leading preventable cause of death worldwide, which makes it
essential to stimulate smoking cessation. The financial cost of smoking cessation
treatment can act as a barrier to those seeking support. We hypothesised that provision
of financial assistance for people trying to quit smoking, or reimbursement of their
care providers, could lead to an increased rate of successful quit attempts. This
is an update of the original 2005 review. The primary objective of this review was
to assess the impact of reducing the costs for tobacco smokers or healthcare providers
for using or providing smoking cessation treatment through healthcare financing interventions
on abstinence from smoking. The secondary objectives were to examine the effects of
different levels of financial support on the use or prescription of smoking cessation
treatment, or both, and on the number of smokers making a quit attempt (quitting smoking
for at least 24 hours). We also assessed the cost effectiveness of different financial
interventions, and analysed the costs per additional quitter, or per quality‐adjusted
life year (QALY) gained. We searched the Cochrane Tobacco Addiction Group Specialised
Register in September 2016. We considered randomised controlled trials (RCTs), controlled
trials and interrupted time series studies involving financial benefit interventions
to smokers or their healthcare providers, or both. Two reviewers independently extracted
data and assessed the quality of the included studies. We calculated risk ratios (RR)
for individual studies on an intention‐to‐treat basis and performed meta‐analysis
using a random‐effects model. In the current update, we have added six new relevant
studies, resulting in a total of 17 studies included in this review involving financial
interventions directed at smokers or healthcare providers, or both. Full financial
interventions directed at smokers had a favourable effect on abstinence at six months
or longer when compared to no intervention (RR 1.77, 95% CI 1.37 to 2.28, I² = 33%,
9333 participants). There was no evidence that full coverage interventions increased
smoking abstinence compared to partial coverage interventions (RR 1.02, 95% CI 0.71
to 1.48, I² = 64%, 5914 participants), but partial coverage interventions were more
effective in increasing abstinence than no intervention (RR 1.27 95% CI 1.02 to 1.59,
I² = 21%, 7108 participants). The economic evaluation showed costs per additional
quitter ranging from USD 97 to USD 7646 for the comparison of full coverage with partial
or no coverage. There was no clear evidence of an effect on smoking cessation when
we pooled two trials of financial incentives directed at healthcare providers (RR
1.16, CI 0.98 to 1.37, I² = 0%, 2311 participants). Full financial interventions increased
the number of participants making a quit attempt when compared to no interventions
(RR 1.11, 95% CI 1.04 to 1.17, I² = 15%, 9065 participants). There was insufficient
evidence to show whether partial financial interventions increased quit attempts compared
to no interventions (RR 1.13, 95% CI 0.98 to 1.31, I² = 88%, 6944 participants). Full
financial interventions increased the use of smoking cessation treatment compared
to no interventions with regard to various pharmacological and behavioural treatments:
nicotine replacement therapy (NRT): RR 1.79, 95% CI 1.54 to 2.09, I² = 35%, 9455 participants;
bupropion: RR 3.22, 95% CI 1.41 to 7.34, I² = 71%, 6321 participants; behavioural
therapy: RR 1.77, 95% CI 1.19 to 2.65, I² = 75%, 9215 participants. There was evidence
that partial coverage compared to no coverage reported a small positive effect on
the use of bupropion (RR 1.15, 95% CI 1.03 to 1.29, I² = 0%, 6765 participants). Interventions
directed at healthcare providers increased the use of behavioural therapy (RR 1.69,
95% CI 1.01 to 2.86, I² = 85%, 25820 participants), but not the use of NRT and/or
bupropion (RR 0.94, 95% CI 0.76 to 1.18, I² = 6%, 2311 participants). We assessed
the quality of the evidence for the main outcome, abstinence from smoking, as moderate.
In most studies participants were not blinded to the different study arms and researchers
were not blinded to the allocated interventions. Furthermore, there was not always
sufficient information on attrition rates. We detected some imprecision but we judged
this to be of minor consequence on the outcomes of this study. Full financial interventions
directed at smokers when compared to no financial interventions increase the proportion
of smokers who attempt to quit, use smoking cessation treatments, and succeed in quitting. There
was no clear and consistent evidence of an effect on smoking cessation from financial
incentives directed at healthcare providers. We are only moderately confident in the
effect estimate because there was some risk of bias due to a lack of blinding in participants
and researchers, and insufficient information on attrition rates. Do interventions
that reduce the cost of smoking cessation treatment increase quit rates, quit attempts
or use of treatments? Background Interventions that reduce or cover the costs of smoking
cessation medication and behavioural support could help smokers quit. We reviewed
the evidence about the effects of financial interventions directed at smokers and
healthcare providers on medication use, quit attempts and successful quitting. Study
characteristics We searched all relevant studies that involved financial interventions
directed at smokers and healthcare providers. For smokers, the aim of the healthcare
financing interventions had to be to encourage the use of smoking cessation treatment
or making successful quit attempts. For interventions directed at healthcare providers,
the intervention had to stimulate the healthcare provider to assist people with quitting
smoking, for example by prescribing smoking cessation treatment. Key results For the
update of this review, we searched studies on the effect of financial interventions
on smoking cessation treatment and success in September 2016. We found six new relevant
studies, resulting in a total of 17 studies. We found 15 studies directed at smokers.
Covering all the costs of smoking cessation treatment for smokers (free treatment)
when compared to providing no financial benefits increased the number of smokers who
attempted to quit (4 studies, 9065 participants), used smoking cessation treatments
(7 studies, 9455 participants), and succeeded in quitting (6 studies, 9333 participants).
We found three studies directed at healthcare providers. The two studies that investigated
the effect of a financial intervention on quit success (2311 participants) did not
clearly show an increase in quit rates. Financial interventions directed at healthcare
providers also did not have an effect on the use of smoking cessation medication (2
studies, 2311 participants). However, financial interventions did increase the number
of smokers who used smoking cessation counselling (3 studies, 25,820 participants).
Information on the costs of the intervention was available for eight studies (33,488
participants). The economic evaluation of the individual studies showed that although
the absolute differences in quitting were small, the costs per person successfully
quitting were low or moderate. Quality of the evidence We concluded that financial
interventions directed at smokers increase the proportion of smokers who attempt to
quit, use smoking cessation treatments, and succeed in quitting. We did not detect
a clear effect on smoking cessation from financial incentives directed at healthcare
providers. This review has some limitations that affect how confident we can be in
the conclusions. The included studies varied substantially in quality and in methods
and design, which makes it difficult to compare results.